» Articles » PMID: 18983947

Cancellous and Cortical Bone Architecture and Turnover at the Iliac Crest of Postmenopausal Osteoporotic Women Treated with Parathyroid Hormone 1-84

Overview
Journal Bone
Date 2008 Nov 6
PMID 18983947
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Treatment with parathyroid hormone [PTH(1-84)] increases lumbar spine bone mineral density and decreases vertebral fractures, but its effects on bone microarchitecture are unknown. We obtained iliac crest biopsies from postmenopausal osteoporotic women given placebo (n=8) or 100 microg PTH(1-84) for 18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure. At 18 months, cancellous bone volume (BV/TV) measured by microcomputed tomography and histomorphometry was 45-48% higher in subjects treated with PTH(1-84) versus placebo, a result of higher trabecular number (Tb.N) and thickness. The higher Tb.N appeared to result from intratrabecular tunneling. Connectivity density was higher and structure model index was lower, indicating a better connected and more plate-like trabecular architecture. Cancellous bone formation rate (BFR) was 2-fold higher in PTH(1-84)-treated subjects, primarily because of greater mineralizing surface. Osteoblast and osteoid surfaces were a nonsignificant 58% and 35%, respectively, higher with PTH(1-84) treatment. Osteoclast and eroded surface were unaffected by PTH(1-84). There were no effects of PTH(1-84) treatment on cortical thickness, or endocortical or periosteal BFR, but cortical porosity tended to be higher. Although cancellous BFR was lower at 24 than at 18 months, measures of cancellous and cortical bone structure were similar at both timepoints. The bone produced by PTH(1-84) had normal lamellar structure and mineralization with no abnormal histology. In conclusion, when compared with placebo, treatment of osteoporotic women with PTH(1-84) was associated with higher BV/TV and trabecular connectivity, with a more plate-like architecture, all consistent with the lower vertebral fracture incidence.

Citing Articles

Transitory Activation and Improved Transition from Erosion to Formation within Intracortical Bone Remodeling in Hypoparathyroid Patients Treated with rhPTH(1-84).

van Dijk Christiansen P, Sikjaer T, Andreasen C, Thomsen J, Bruel A, Hauge E JBMR Plus. 2023; 7(12):e10829.

PMID: 38130746 PMC: 10731115. DOI: 10.1002/jbm4.10829.


MMP14 cleaves PTH1R in the chondrocyte-derived osteoblast lineage, curbing signaling intensity for proper bone anabolism.

Chu T, Chen P, Yu A, Kong M, Tan Z, Tsang K Elife. 2023; 12.

PMID: 36892459 PMC: 10036123. DOI: 10.7554/eLife.82142.


Reference Intervals for Bone Histomorphometric Measurements Based on Data from Healthy Premenopausal Women.

Qiu S, Divine G, Warner E, Rao S Calcif Tissue Int. 2020; 107(6):543-550.

PMID: 32814991 PMC: 7606320. DOI: 10.1007/s00223-020-00748-6.


Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial.

Tabatabaei-Malazy O, Norani M, Heshmat R, Qorbani M, Vosoogh A, Afrashteh B Iran J Public Health. 2018; 47(9):1336-1344.

PMID: 30320008 PMC: 6174042.


The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry.

Rubin M, Zhou H, Cusano N, Majeed R, Omeragic B, Gomez M J Bone Miner Res. 2018; 33(11):1931-1939.

PMID: 29972871 PMC: 6546298. DOI: 10.1002/jbmr.3543.